Composition GHK-Cu: 50 mg BPC-157: 10 mg TB-500 (Thymosin Beta 4): 10 mg Appearance: lyophilized powder in a sealed research vial Research Focus (non-clinical) Combined evaluation of copper peptide, BPC-157, and TB-500 in in-vitro or ex-vivo assay systems Assay development, including chromatographic separation of three co-formulated peptides Stability characterization of a three-analyte lyophilized blend under laboratory storage conditions Method documentation for HPLC/LC-MS identity and purity assessments Documentation Analysis Report Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
GHK-Cu stimulates the production of collagen types I, II, and III, as well as elastin and the glycosaminoglycans that give skin its volume and hydration
FIGURE 6 3.6 GHK-Cu promoted mucosal healing via inhibiting STAT3 activation To investigate the role of STAT3 activation in facilitating the therapeutic benefits of GHK-Cu, we meticulously designed and executed STAT3 knockdown experiments in vitro , utilizing the co-culture model
Anti-glycation effect Glycation is the process by which sugar (glucose, fructose) reacts non-enzymatically with proteins to form Advanced Glycation End-products (AGEs)
TB500 is investigated for its association with actin polymerization dynamics and intracellular actin sequestration, which directly influences cell motility, differentiation, and structural reorganization
Compounded-unit conversions should never be inferred from a generic chart alone